<DOC>
	<DOCNO>NCT00370552</DOCNO>
	<brief_summary>The purpose clinical research study learn ixabepilone plus bevacizumab effective shrink stop growth cancer give first-line chemotherapy participant metastatic breast cancer . The study also assess safety combination treatment .</brief_summary>
	<brief_title>A Trial 2 Schedules Ixabepilone Plus Bevacizumab Paclitaxel Plus Bevacizumab Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : Locally recurrent metastatic breast cancer , previously untreated chemotherapy advance disease . At least 1 target lesion per RECIST criterion . Locally recurrent disease must amenable resection curative intent . No previous cytotoxic chemotherapy locally recurrent/metastatic disease . Relapse 12 month complete prior adjuvant neoadjuvant taxane therapy . No previous breast cancer know overexpress amplify human epidermal growth factor receptor 2 gene . Prior hormonal therapy adjuvant , recurrent , metastatic setting allow must discontinue least 2 week randomization . Karnofsky performance status 80 100 Eastern Cooperative Oncology Group performance status 0 1 . Estimated life expectancy least 12 week . Recovery recent therapy ( except alopecia ) , include chemotherapy , immunotherapy , biologic therapy , investigational product . Any therapy must complete least 3 week randomization least 6 week use nitrosourea , mitomycin . Recovery recent surgery radiation therapy . At least 1 week since minor surgery and/or focal/palliative radiation therapy ; least 3 week radiation ; least 4 week major surgery ; least 8 week liver resection , thoracotomy , neurosurgery . Absolute neutrophil count ≥1500/mm^3 . Hemoglobin ≥9 g/dL . Platelets ≥100,000/mm^3 . Total bilirubin ≤1.5 time upper limit normal ( ULN ) . Aspartate aminotransferase alanine aminotransferase ≤2.5*ULN . Normal partial thromboplastin time either international normalized ratio prothrombin time &lt; 1.5*ULN . Serum creatinine ≤1.5*ULN 24hour creatinine clearance &gt; 60 mL/min . Urine dipstick proteinuria &lt; 2+ ( negative , trace , +1 ) . Participants ≥2+ proteinuria baseline undergo 24hour urine collection demonstrate ≤1g protein 24 hour eligible . Exclusion criterion : Women childbearing potential ( WOCBP ) unwilling unable use acceptable method birth control avoid pregnancy entire study period 6 month treatment bevacizumab . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Sexually active fertile men , whose partner WOCBP , use adequate method birth control . Evidence baseline sensory motor neuropathy . Serious infection nonmalignant medical illness uncontrolled control could jeopardize therapy . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess , serious gastric ulcer , bone fracture within 6 month study entry . History hypertensive crisis hypertensive encephalopathy . Significant vascular disease . Clinically significant cardiovascular disease . Baseline leave ventricular ejection fraction multiplegated acquisition scan echocardiogram subject prior exposure anthracyclines within institutional normal limit . Symptomatic peripheral vascular disease . History high dose chemotherapy bone marrow transplant peripheral blood stem cell transplant within previous 2 year . Evidence bleed diathesis coagulopathy . Prior treatment epothilone antiangiogenic agent . Concurrent nonhealing wound , ulcer , fracture . Any current history brain and/or leptomeningeal metastasis . Psychiatric disorder condition render participant incapable complying requirement protocol . Any concurrent active malignancy nonmelanoma skin cancer carcinoma situ cervix . Known allergy study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>